FDA recommended that Compass Therapeutics conduct a survival-benefit trial before submitting a BLA for tovecimig, despite data showing a 56% reduction in disease-progression risk. The feedback matters because the company says it plans further FDA discussions and believes the existing COMPANION-002 results support moving toward a BLA without another trial.

Key Highlights

  • FDA recommended a survival-benefit trial before Compass Therapeutics submits a BLA for tovecimig.
  • Tovecimig plus paclitaxel produced an 18.0% objective response rate versus 5.3% for paclitaxel alone.
  • Compass Therapeutics plans further discussions with FDA as it prepares a potential BLA submission.

Compass Therapeutics, Inc. (NASDAQ: CMPX) is a Pharmaceuticals: Major company. FDA feedback now calls for survival-benefit evidence before a Biologics license application for tovecimig in previously treated, advanced biliary tract cancer. Compass Therapeutics says it does not believe another trial is warranted before a BLA based on existing study results and the urgent medical need in BTC.

FDA Recommendation Adds Survival Evidence Requirement

Tovecimig was evaluated with paclitaxel in the COMPANION-002 study, where objective response rate improved to 18.0% from 5.3% with paclitaxel alone, with a p-value of 0.0228. Median progression-free survival reached 4.7 months versus 2.6 months, while the hazard ratio was 0.44 and the p-value was below 0.0001. Overall-survival analysis was affected by extensive crossover and prolonged survival among patients who moved from the control group to tovecimig, and the result did not reach statistical significance. The treatment’s safety profile was generally consistent with earlier tovecimig studies. Compass intends to continue engaging with FDA while preparing a BLA submission for tovecimig.